

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshiaki Sai, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<http://www.daiichisankyo.com/>

**Daiichi Sankyo Announces Reorganization, Reinforcement and Renaming of
R&D-related Japan Subsidiary**

Tokyo, Japan (August 26, 2011) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will reorganize, reinforce, and rename its domestic subsidiary DAIICHI SANKYO RD ASSOCIE CO., LTD. From October 1, the subsidiary will be known as DAIICHI SANKYO RD NOVARE CO., LTD.

The current DAIICHI SANKYO RD ASSOCIE collaborates with other business units and companies within the Daiichi Sankyo Group to support new drug innovation. Daiichi Sankyo will reinforce DAIICHI SANKYO RD ASSOCIE's existing capabilities while also centralizing basic pharmaceutical innovation technologies within it. The renamed DAIICHI SANKYO RD NOVARE subsidiary will function as a global research and development platform for the Group, accelerating innovation in first-in-class pharmaceuticals.

1. New Company Name

New company name	Previous company name
DAIICHI SANKYO RD NOVARE CO., LTD.	DAIICHI SANKYO RD ASSOCIE CO., LTD.

2. Date of Change

October 1, 2011

###

Profile of DAIICHI SANKYO RD NOVARE CO., LTD.

Date of establishment	October 3, 2006
President	Hideyuki Haruyama
Capitalization	50 million yen
Projected number of employees (as of October 1, 2011)	Around 300
Core business overview	<ul style="list-style-type: none"> • Custom production of research materials and intermediates for drug discovery and development • Contract assay development and quantitative and/or qualitative analysis of drug substances • Technology based drug discovery support and alliance • Consultation for the evaluation and application of the novel technological platform for drug discovery • Contract Clinical development